The core risk is sequencing: the 108Q proof gate still sits ahead of real scale, and most other positives only matter if that gate clears. Rigetti has enough liquidity to keep trying, but revenue is concentrated,
gross margin is weak, and the stock already assumes a large part of the science works. That makes downside mostly a trust and multiple problem, not an immediate solvency problem.